Bezuclastinib
Product Specifications
UNSPSC Description
Bezuclastinib (CGT9486) is an orally active, highly selective tyrosine kinase inhibitor with potent activity against KIT D816V. Bezuclastinib can be used for the research of nonadvanced systemic mastocytosis (NonAdvSM)[1].
Target Antigen
c-Kit
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bezuclastinib.html
Solubility
DMSO : 80 mg/mL (ultrasonic)
Smiles
O=C(C1=NNC(C)=C1C)NC2=CN=C3NC(C4=CC=CC=C4)=CC3=C2
Molecular Weight
331.37
References & Citations
[1]Guarnieri A, et al. Preclinical Data with KIT D816V Inhibitor Bezuclastinib (CGT9486) Demonstrates High Selectivity and Minimal Brain Penetrance. Blood. 2021, 138: 4595. |[2]Guarnieri A, et al. Preclinical data identifies bezuclastinib as a differentiated KIT inhibitor with unique selectivity to KIT D816V and minimal evidence of brain penetration. MOLECULAR CANCER THERAPEUTICS. 2021, 20(12).
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-145557/Bezuclastinib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-145557/Bezuclastinib-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
1616385-51-3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Mouse Monoclonal ILT7/CD85g/LILRA4 Antibody (17G10.2) [Janelia Fluor 646]](https://cdn.genprice.uk/genprice/genprice2.png)
NBP2-62226JF646 0.1 mL
Mouse Monoclonal ILT7/CD85g/LILRA4 Antibody (17G10.2) [Janelia Fluor 646]
Ask
View Details 